ABSTRACT
Introduction Brucellosis is a neglected zoonotic disease that affects humans and animals and can lead to severe illness in humans and financial losses for households that rear livestock. The study aimed to investigate the seroprevalence of human Brucella antibodies and associated risk factors among patients seeking medical attention at community hospitals.
Methods A cross-sectional seroepidemiological study was conducted from 21st April 2021 to 21st April 2024 among patients seeking medical attention at community hospitals in selected districts of Western province in Zambia. 225 blood samples were collected from consenting participants. Sera were separated and analysed for anti-Brucella antibodies using the Rose Bengal Test (RBT) and Competitive enzyme-linked immunosorbent assay (c-ELISA) in parallel. A questionnaire was administered to obtain epidemiological data related to exposure to the Brucella pathogen. The data obtained were coded and entered in the Micro-Soft Excel 2013® and analysed using STATA version 15®.
Results 197 sera samples were found acceptable for testing and analysis for this study, out of these, the seroprevalence of Brucella antibodies was 18.3% (n=36, 95% CI=0.13-0.24) and 4.57% (n=9, 95% CI=-0.68-0.28) on RBT and c-ELISA respectively.Among the risk factors considered, the number of animals was statistically significantly associated with Brucella seropositivity (OR 6.49, 95% CI=1.10-38.13, p-value = 0.039).
Conclusions Brucella antibodies are prevalent among patients attending health facilities in the Western province of Zambia. The number of animals were significantly associated with the Brucella seropositivity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from Excellence in Research Ethics and Science (ERES) (Ref No. 2018-Dec-004), the National Health Research Authority (NHRA), and the Ministry of Health before the commencement of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
